A high MGMT expression in cells is the predominant mechanism underlying tumor resistance to alkylating agents.3, 4, 5, 6 Currently, it has been shown that MGMT methylation or protein expression can be used as useful predictive biomarkers during temozolomide chemotherapy.7, 8, 9, 10 MGMT methylation status testing by methylation‐specific PCR, immunohistochemistry (IHC) or pyrosequencing has been established as a routine molecular pathological technique for patients with glioma. The gene discussed is MGMT; the disease is central nervous system cancer.